Oppenheimer analyst Jay Olson maintained a Buy rating on Amgen Inc (NASDAQ:AMGN) on Sunday, setting a price target of $274, which is approximately 15.44% above the present share price of $237.36.
Olson expects Amgen Inc to post earnings per share (EPS) of $3.45 for the fourth quarter of 2020.
The current consensus among 21 TipRanks analysts is for a Moderate Buy rating of shares in Amgen, with an average price target of $258.31.
The analysts price targets range from a high of $304 to a low of $215.
In its latest earnings report, released on 09/30/2020, the company reported a quarterly revenue of $6.42 billion and a net profit of $2.45 billion. The company's market cap is $138.18 billion.
According to TipRanks.com, Oppenheimer analyst Jay Olson is currently ranked with 1 stars on a 0-5 stars ranking scale, with an average return of -0.6% and a 42.51% success rate.
Amgen, Inc. is a biotechnology company, which engages in the discovery, development, manufacture and marketing of human therapeutics. Its products include the following brands: Aranesp, BLINCYTO, Corlanor, ENBREL, EPOGEN, IMLYGIC, KYPROLIS, Neulasta, NEUPOGEN, Nplate, Parsabiv, Prolia, Repatha, Sensipar, Vectibix, and XGEVA. The company was founded by William K. Bowes, Jr., Franklin Pitcher Johnson, Jr., George B. Rathmann and Joseph Rubinfeld on April 8, 1980 and is headquartered in Thousand Oaks, CA.